Study Conclusions: Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.
While the list of crimes committed by authorities during the COVID-19 pandemic is a long one, perhaps the biggest crime of all is the purposeful suppression of safe and effective treatments. At this point, it seems quite clear that this was done to protect the COVID jab rollout.
The COVID shots were brought to market under emergency use authorization (EUA), which can only be obtained if there are no other alternatives available. In a sane world, the COVID gene therapies would never have gotten an EUA, as there are several safe and effective treatment options available.
What makes ivermectin particularly useful in COVID-19 is the fact that it works both in the initial viral phase of the illness, when antivirals are required, as well as the inflammatory stage, when the viral load drops off and anti-inflammatories become necessary. It’s been shown to significantly inhibit SARS-CoV-2 replication in vitro,1 speed up viral clearance and dramatically reduce the risk of death.
Gold Standard Review Supports Use of Ivermectin
Dr. Tess Lawrie, a medical doctor, Ph.D., researcher and director of Evidence-Based Medicine Consultancy Ltd (see video in original article linked below) in the U.K., has been trying to get the word out about ivermectin. To that end, she helped organize the British Ivermectin Recommendation Development (BIRD) panel and the International Ivermectin for COVID Conference, which was held online, April 24, 2021.
Twelve medical experts from around the world shared their knowledge during this conference, reviewing mechanism of action, protocols for prevention and treatment, including so-called long-hauler syndrome, research findings and real world data. All of the lectures, which were recorded via Zoom, can be viewed on Bird-Group.org.
Lawrie has published several systematic reviews and meta-analyses of studies looking at ivermectin for the prevention and treatment of COVID-19 infection. A rapid review performed on behalf of the Front Line COVID-19 Critical Care Alliance (FLCCC) in the U.S., January 3, 2021, found the drug “probably reduces deaths by an average 83% compared to no ivermectin treatment.”7
Her February 2021 meta-analysis, which included 13 studies, found a 68% reduction in deaths. This is an underestimation of the beneficial effect, because one of the studies included used hydroxychloroquine (HCQ) in the control arm. Since HCQ is an active treatment that has also been shown to have a positive impact on outcomes, it’s not surprising that this particular study did not rate ivermectin as better than the control treatment (which was HCQ).
Two months later, March 31, 2021, Lawrie published an updated analysis that included two additional randomized controlled trials. This time, the mortality reduction was 62%. When four studies with high risk of bias were removed during a subsequent sensitivity analysis, they ended up with a 72% reduction in deaths. (Sensitivity analyses are done to double-check and verify results. Since the sensitivity analysis rendered an even better result, it confirms the initial finding. In other words, ivermectin is unlikely to reduce mortality by anything less than 62%.)
Lawrie reviewed the February and March analyses and other meta-analyses in an interview with Dr. John Campbell, featured in “More Good News on Ivermectin.” Lawrie has now published her third systematic review. According to this paper, published June 17, 2021 in the American Journal of Therapeutics:8
“Meta-analysis of 15 trials found that ivermectin reduced risk of death compared to no ivermectin (average risk ratio 0.38 …) … Low-certainty evidence found that ivermectin prophylaxis reduced COVID-19 infection by an average 86% … Secondary outcomes provided less certain evidence.
Low-certainly evidence suggested that there may be no benefit with ivermectin for ‘need for mechanical ventilation,’ whereas effect estimates for ‘improvement’ and ‘deterioration’ clearly favored ivermectin use. Severe adverse events were rare among treatment trials …”